Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 4 Head and Neck Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Uterine Cervical Neoplasms 2 Nasopharyngeal Neoplasms 2 Esophageal Neoplasms 2 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Nasopharyngeal Diseases 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Carboplatin 17 Cisplatin 14 Paclitaxel 12 Pemetrexed 11 pembrolizumab 9 Gemcitabine 7 Docetaxel 6 Sorafenib 5 osimertinib 4 durvalumab 4 130-nm albumin-bound paclitaxel 4 padeliporfin 3 cabozantinib 3 atezolizumab 3 Taxes 3 Radiotherapy 3 Mitomycin 3 Magnetic Resonance Spectroscopy 3 Cetuximab 3 Bevacizumab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 trifluridine tipiracil drug combination 2 regorafenib 2 olaparib 2 Sunitinib 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Nivolumab 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma × nimotuzumab × Clear all

NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn

Carcinoma, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡